How to Help Your Patients Find Venofer in Stock: A Provider's Guide

One of the most difficult conversations in nephrology practice is telling a patient who depends on Venofer (iron sucrose injection) that your facility doesn't have it. Unlike medication shortages in other specialties, IV iron disruptions directly threaten the stability of iron and hemoglobin levels in patients whose kidneys can no longer regulate these processes normally.

This guide is designed for nephrologists, nephrology NPs/PAs, infusion nurses, and practice managers who want to be prepared — and who want to give their patients the best possible support when Venofer supply runs tight.

Step 1: Communicate Early and Clearly With Patients

The moment you learn Venofer supply may be constrained, notify your patients before they show up for treatment and find out at the clinic. A short patient letter or phone call explaining:

What is happening with the supply of their IV iron medication

What the plan is — are you switching to generic iron sucrose, Ferrlecit, or another alternative?

That their safety and treatment continuity is the priority

When they can expect next steps or an update

Proactive communication reduces patient anxiety significantly and gives patients time to take action rather than arriving at their dialysis session to an unexpected disruption.

Step 2: Exhaust Internal Options First

Before asking patients to seek care elsewhere, check every internal option:

Contact your distributor: Ask specifically about generic iron sucrose availability — it often has separate inventory from brand-name Venofer and may not be impacted by the same supply constraint.

Check with your GPO: Group purchasing organizations sometimes have access to alternative distributors or secondary market sources during shortage periods.

Review formulary alternatives: Ferrlecit (sodium ferric gluconate) is often stocked at dialysis centers and may be available when iron sucrose is not.

Step 3: Help Patients Identify Nearby Facilities With Supply

If your facility genuinely cannot provide IV iron and a therapeutic substitution is not feasible, patients may need to receive treatment at a different location temporarily. This is far easier for NDD-CKD or PDD-CKD patients receiving infusions than for hemodialysis patients, who are typically assigned to a specific dialysis center and cannot simply walk into another.

For non-dialysis infusion patients, you can:

Write a referral to a nearby infusion center or hospital outpatient infusion suite and confirm they have iron sucrose in stock before sending the patient

Send clinical documentation including iron studies, CKD stage, and current treatment plan to facilitate a smooth handoff

Recommend that patients use medfinder to locate available supply — it calls providers in their area and reports back which ones have Venofer or iron sucrose in stock

Step 4: Facilitate Prior Authorizations Proactively

If you plan to switch patients to Feraheme or Injectafer during a shortage, don't wait until the patient is already missing doses to start the prior authorization process. Begin requests immediately when you identify a supply problem. Key tips for faster approval during shortage scenarios:

Attach distributor-issued shortage confirmation to all PA requests

Include patient's iron labs (ferritin, TSAT) and hemoglobin — urgency is demonstrated by data

For urgent cases, call the payer directly and request peer-to-peer review — this can reduce turnaround time from weeks to days

For Medicare Part B patients on hemodialysis, most IV iron products do not require prior authorization, so prioritize getting those patients treated first

39,483+ patients found their medications in stock

39K+

Find Venofer In Stock Today →

Step 5: Triage Patients by Clinical Urgency

When supply is constrained and not all patients can be treated immediately, use laboratory data to triage:

High priority: Ferritin <100 ng/mL or TSAT <15% with hemoglobin <10 g/dL — treat as soon as possible

Medium priority: Ferritin 100–200 ng/mL or TSAT 15–20% with hemoglobin 10–11 g/dL — schedule as soon as supply allows

Maintenance phase: Ferritin >500 ng/mL and TSAT >30% — can safely defer additional iron until supply is restored

Using medfinder in Your Practice

Coordinating care across facilities during a shortage consumes significant staff time. medfinder's provider platform streamlines the process of locating infusion providers with available IV iron in your patients' areas. For your patients who are managing the search themselves, direct them to medfinder.com. Also see our provider shortage guide for clinical decision-making support.